ZYBERNO
Stock Report
Updated Aug 27, 2026

Telix Pharmaceuticals Limited (TLPPF)

Healthcare • OTC

$11.37

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
11.0/100
POOR BUSINESS
Telix Pharmaceuticals Limited (TLPPF) scores 11/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
Margin of Safety unavailable — insufficient data for the owner-earnings DCF.
Is the market underestimating or overestimating what this business is capable of going forward?
-37.7%
Market Overestimates
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.98x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (3.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Telix Pharmaceuticals Limited (TLPPF) stock report — Zyberno Score 11/100 (POOR BUSINESS). Full financial analysis on Zyberno.

According to Zyberno's DCF model, Telix Pharmaceuticals Limited (TLPPF) shows a Brina Gap of -37.7%, which weakens the case: based on the company's ROIC (3.3%) and reinvestment rate (19.2%), the business can fundamentally grow at 0.6% — but the current enterprise value implies the market expects 38.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:11.37
Market Cap:$3.85B

Valuation Multiples (2)

P/B Ratio:9.27x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$4.12B
Ev Ebitda Ratio:80.40x

Price Action & Momentum (3)

Momentum Percentile:17 / 100
% of 52-Week High:60.0%
B. Profitability Assessment

Return Metrics (5)

Reinvestment Rate:19.2%
Fundamental Growth Rate (g):0.6%
Market-Implied Growth Rate:38.3%

Margin Analysis (1)

Ebitda Margin:6.4%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.43x
Quick Ratio:1.27x
Cash Ratio:0.61x

Leverage Analysis (3)

Debt To Equity Ttm:0.98x
Debt-to-Equity Ratio:0.98x
Debt To Ebitda:7.91x

Coverage Ratios (2)

Interest Coverage Ratio:0.73x
Times Interest Earned:0.73

Capital Structure (4)

Working Capital:98,656,000.00
Cash And Cash Equivalents:141,866,000.00
Long Term Debt:$391.91M
Net Debt:$263.16M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$803.79M
Cost Of Revenue Ttm:$377.36M

Profitability Breakdown (2)

$426.44M$29.78M

Bottom Line Performance (3)

-$7.13M
Income Before Tax:$0.00
Ebitda Ttm:51,185,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$1.86M
Interest Expense:40,868,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:6.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.16B
Current Assets:$330.28M
Ppe Net:58,661,000.00
Goodwill:198,988,000.00
Intangible Assets:$592.82M

Liability Structure (4)

Total Liabilities:748,610,000.00
Current Liabilities:231,624,000.00
Long Term Debt:$391.91M
Short Term Debt:$13.11M

Equity & Capital (3)

Equity:$415.38M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:129,202,000.00
Inventory:37,080,000.00
Accounts Payable:71,661,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$17.29M-$42.99M

Investment Activities (1)

Investing Cash Flow:-$285.92M

Financing Activities (3)

Financing Cash Flow:-$3.72M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.02

Revenue & Cash Per Share (2)

Sales Per Share Ttm:2.37
Operating Cash Flow Per Share:-$0.05

Book Value & Capital (2)

Book Value Per Share:$1.23
Cash Per Share:0.42

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.69x
Working Capital Turnover Ttm:8.15x

Receivables Management (2)

Receivables Turnover Ttm:6.22x
Days Sales Outstanding Ttm:58.67

Inventory Management (2)

Inventory Turnover Ttm:10.18x
Days Inventory Outstanding Ttm:35.87

Payables & Cash Cycle (2)

Days Payable Outstanding:69.31
Cash Conversion Cycle:25.22
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (4)

Reinvestment Rate:19.2%
Fundamental Growth Rate (g):0.6%
Market-Implied Growth Rate:38.3%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:TLPPF
Company Name:Telix Pharmaceuticals Limited
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:Australia

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:338.78M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-27 02:06:14 UTC
Data Timestamp:2026-08-27T02:06:14.008883
Scroll to Top